MTTI Builds an Albumin-Binding Radiopharmaceutical Platform

Molecular Targeting Technologies is building a radiopharmaceutical platform around a deceptively practical question: what if a targeted therapy could stay in circulation long enough to deliver more radiation where it is wanted? The West Chester, Pennsylvania clinical-stage biotech uses reversible albumin binding to alter how targeted radioactive compounds move through the body.

Chairman, President, and CEO Koon Yan "Chris" Pak leads MTTI alongside a team with experience in nuclear medicine, drug development, regulation, chemistry, and business development. The company calls its Evans Blue-based platform EvaThera, and its pipeline spans radiotherapeutics for neuroendocrine tumors, thyroid cancer, lung cancer, and glioblastoma, plus molecular imaging and fluorescence-guided surgery programs.

MTTI matters now because radiopharmaceutical oncology has moved from a specialized corner of nuclear medicine into a crowded strategic market. The next advantage may not come only from finding another tumor target. It may come from controlling pharmacokinetics well enough to improve tumor exposure without simply increasing administered radioactivity.

About Molecular Targeting Technologies

MTTI is a privately held biotechnology company whose public record stretches back at least to 2008. Its current company pages describe a clinical-stage business developing targeted radiopharmaceuticals and molecular imaging technologies for cancer. A separate legacy commerce operation continues to offer research reagents and imaging products, including fluorescent labels and molecular probes.

The company's development model combines licensed academic technology, internal chemistry and translational work, government-supported research, clinical collaborations, and external manufacturing or isotope-supply relationships. MTTI received worldwide commercialization rights from the National Institutes of Health for targeted theranostics built on the Evans Blue platform, and it has used public grants and private financing to move programs toward clinical testing.

That structure looks less like a single-asset startup and more like a compact translational engine. It also creates a demanding operating model. Intellectual property, isotope availability, CMC, dosimetry, clinical design, and regulatory evidence all have to move together. A clever molecule is only the opening bid.

EvaThera Engineers Time Into the Drug

EvaThera uses an Evans Blue derivative to create reversible binding between a targeted radiopharmaceutical and albumin. Albumin remains in circulation longer than many small targeting molecules. MTTI's thesis is that borrowing some of that residence time can increase the opportunity for a radiopharmaceutical to reach and remain in a tumor.

The lead example is EBTATE, a long-acting somatostatin analogue aimed at SSTR2-positive tumors. Several peer-reviewed studies have examined 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. In 2026, MTTI reported clinical experience across 81 GEP-NET patients and tumor retention lasting up to 15 days. Those results are encouraging platform evidence, but they do not make EBTATE an approved therapy or settle the questions of optimal dosing, comparative safety, and durable benefit.

An NIH-sponsored Phase 1/2 study is also registered to evaluate 177Lu-DOTA-EB-TATE in metastatic, radioactive-iodine-nonresponsive Hürthle-cell thyroid cancer. The registry listed that study as not yet recruiting at its June 5, 2026 update. That is an important distinction: MTTI has human evidence, but the platform still has a long regulatory road.

EBRGD Tests Whether the Platform Can Travel

EBRGD applies the same albumin-binding logic to a different target, integrin αvβ3. MTTI is developing 177Lu-EBRGD for cancers including non-small cell lung cancer and glioblastoma. A peer-reviewed NSCLC study found stronger tumor accumulation and retention than a non-albumin-binding comparator in patient-derived xenograft models, with antitumor activity that varied with integrin expression.

That evidence is preclinical. The bridge to patients now runs through a five-year National Cancer Institute award announced at $3.17M. NIH records list $637,529 for the first budget period, while MTTI describes the full program as supporting preclinical evaluation, drug-product manufacturing, regulatory preparation, and planned clinical development.

The strategic significance is bigger than one lung cancer program. If EBRGD advances, MTTI will have evidence that EvaThera can support more than one targeting peptide and disease setting. If it stalls, the company will learn how much of EBTATE's profile belongs to the platform and how much belongs to the individual molecule.

The Pipeline Extends Beyond Radiotherapy

MTTI's development history also includes diagnostics and research tools. Its Cmetglo program uses a sprayable near-infrared probe intended to help surgeons distinguish tumor from normal tissue during cytoreductive procedures. The program has received NCI SBIR support and involves work with the National Cancer Centre Singapore and Weill Cornell Medicine.

Government portfolio data gives the broader picture. SBIR.gov reports 19 Phase I awards, 5 Phase II awards, and $11.75M awarded to MTTI. The company also announced a 2019 Series A financed by MTT Holding Company and led by Comway Capital USA, though it did not disclose the amount.

This mix of grants, licensing, clinical partners, and private capital is a familiar biotech survival system. At MTTI, it is also part of the product strategy. Each program builds another relationship across the machinery required to deliver a radiopharmaceutical, from isotope supply and manufacturing to imaging, clinical sites, and regulation.

Leadership Built Around Translation

Pak's official biography says he has more than three decades in biopharmaceutical research and drug development, contributed to more than 20 IND applications, and authored or co-authored more than 90 publications. Before MTTI, he held scientific and leadership roles at Centocor, now part of Johnson & Johnson. At MTTI, he has been the central operator behind EvaThera and the company's radiopharmaceutical pipeline.

The current leadership roster adds Norman LaFrance as Chief Medical Strategy Officer, Jeffrey A. Mattis as Senior Vice President of Scientific & Regulatory Affairs, Brian D. Gray as Senior Vice President of Research, Michael Silvon as Senior Vice President of Business Development, and Jianwei Xu as Chief Business Officer. The group is unusually heavy on translation, regulation, and commercialization for a company that public databases describe as small.

No current MTTI careers page or verified open role was found. The better signal is the work itself. EBTATE clinical development, an NIH-sponsored thyroid cancer study, the EBRGD grant, and active partnering outreach all create execution demands, but they do not justify calling the company an active recruiter.

Why MTTI Matters Now

Radiopharmaceutical development has become a contest over targets, isotopes, manufacturing capacity, clinical evidence, and operating discipline. MTTI is adding another variable to that contest: residence time. EvaThera treats pharmacokinetics as something that can be deliberately engineered into a targeted therapy rather than accepted as a fixed property of the targeting molecule.

The platform still has to prove itself program by program. EBTATE needs stronger comparative and regulatory evidence. EBRGD must cross the gap from animal models into a credible human development path. Cmetglo has to show that faster intraoperative visualization can become a reproducible tool rather than an interesting demonstration.

That is why MTTI is worth tracking. The company is not selling certainty. It is assembling a body of human data, licensed technology, federal support, and development infrastructure around a testable idea: better control of circulation and tumor retention could make targeted radiation more efficient. In this market, time inside the body may become as strategic as the target itself.